ASGE Annual GI Advanced Practice Provider Course (Virtual) (Day One) | March 2026-Bariatric and Endoluminal Interventions What APPs Should Know

Pdf Summary

This presentation reviews bariatric and endoluminal (endoscopic) weight-loss interventions and practical “red flags” for advanced practice providers. It highlights a major treatment gap in obesity care: while obesity is prevalent, many patients do not want surgery and only about 1% of eligible patients undergo bariatric surgery. The “modern metabolic toolbox” is positioned as a continuum from lifestyle therapy and anti-obesity medications to surgery, with endoluminal options helping bridge the gap.<br /><br />Key bariatric surgery considerations include expected total body weight loss (roughly 30–45% depending on procedure) and urgent post-op warning signs: tachycardia may signal an anastomotic leak (and can be masked by beta blockers), epigastric pain radiating to the back may indicate an internal hernia (a surgical emergency; CT “swirl sign,” labs may be normal), and persistent vomiting may reflect an anastomotic stricture with risk of thiamine deficiency/Wernicke’s encephalopathy. Lifelong nutritional monitoring is emphasized (baseline, 3, 6, 12 months, then annually), including bone health, anemia, “transfer addiction,” and bariatric multivitamins.<br /><br />Endoluminal therapies discussed are intragastric balloon (IGB) and endoscopic sleeve gastroplasty (ESG). IGB is indicated for BMI 30–40 after failed lifestyle therapy; it is fully reversible and produces ~10–15% TBWL over 6 months but requires PPI use and a second endoscopy for removal, with risks such as ulcer/bleeding, perforation, migration, hyperinflation, pancreatitis, and intolerance. ESG is FDA-approved for BMI 30–50, has a low risk profile and ~1 week recovery, is semi-permanent, and typically yields 13–20% TBWL at 12 months; contraindications include cirrhosis, esophageal stricture, large hiatal hernia, need for gastric surveillance, Crohn’s disease, and severe cardiopulmonary disease. Endobariatric red flags include tachycardia/fever/left shoulder pain (leak), tachycardia with melena (upper GI bleed), dehydration/constipation, and early hunger/weight regain (suture failure). A staged post-procedure diet progression is provided.<br /><br />The talk also stresses lifestyle fundamentals (high-protein, lower-carb; fiber for maintenance; protein targets ~1.2–1.5 g/kg lean body weight) and exercise to prevent sarcopenia (150–300 minutes/week plus resistance training). A case illustrates that symptoms may have unrelated causes (large benign mucinous cystadenoma found months after ESG). The conclusion summarizes indications: surgery for BMI ≥40 or ≥35 with severe comorbidities; endoluminal options for BMI 30–50; lifestyle changes for all.

Asset Subtitle

Sarah Kosinski, DNP, APRN, FNP-BC

Meta Tag

Concept Obesity Treatment

Concept Lifestyle Modification

Concept Anti-Obesity Medication

Concept Bariatric Surgery

Concept Endoluminal Therapy

Keywords

bariatric surgery

endoluminal weight-loss interventions

endoscopic sleeve gastroplasty (ESG)

intragastric balloon (IGB)

total body weight loss (TBWL)

postoperative red flags (anastomotic leak, internal hernia, stricture)

nutritional monitoring and bariatric multivitamins

thiamine deficiency and Wernicke’s encephalopathy

obesity treatment gap and metabolic toolbox continuum

diet progression, high-protein nutrition, and exercise to prevent sarcopenia

Obesity Treatment

Lifestyle Modification

Anti-Obesity Medication

Bariatric Surgery

Endoluminal Therapy